Data from three Immune Tolerance Network (ITN) type 1 diabetes studies will be presented at the upcoming European Association for the Study of Diabetes (EASD) meeting on October 1-5, 2012 in Berlin, Germany.
Mario Ehlers, MD, PhD (Immune Tolerance Network) will present preliminary data from the ITN’s RETAIN Study in an oral abstract: “Alpha-1 antitrypsin therapy in new-onset type 1 diabetes: interim results from Part I of the RETAIN study” (Thursday, October 4th, 10:45-11:00am). More information about the RETAIN study here.
Kevan Herold, MD (Yale University) will present data on features that distinguish treatment responders and non-responders in the ITN’s AbATE study in a poster presentation titled: “Metabolic parameters at baseline identify clinical responders to teplizumab 2 years after diagnosis of type 1 diabetes” (Wednesday, October 3rd, 1:15pm-2:15pm).
Stephen Gitelman, MD (University of California, San Francisco) will present the primary clinical results of the ITN’s START study in a poster presentation titled: “Effect of anti-thymocyte globulin (ATG) on preserving beta cell function in new-onset type 1 diabetes” (Wednesday, October 3rd, 1:15pm-2:15pm). More information about the START study here.
More details about the EASD abstracts and the scientific program can be found here.